Roberto Bellini bought $2.0M of IKT
director at Inhibikase Therapeutics, Inc.. 1,460,000 shares at an average of $1.37, traded Oct 21, 2024, filed Oct 23, 2024.
Score components
- +15RoleDirector
- +25Trade size$2.0M at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -4.9%, 3m +15.2%, 6m -11.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-116785, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 21, 2024 | POpen-market purchase Common Stockindirect: See footnote | +1,460,000 | $1.37 | $2.0M | 1,460,000 | Oct 23, 2024 |
| Oct 21, 2024 | AGrant or award Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Oct 23, 2024 |
Related signals
Other insiders at Inhibikase Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 53Moderate | IKTbuy Inhibikase Therapeutics, Inc. | Sands Capital Life Sciences Pulse Fund II, L.P. owner | $3.0M 2,068,965 shares | +19% | |
| 56Moderate | Inhibikase Therapeutics, Inc. | Amit Munshi director | $500k 365,000 shares | - | |
| 50Moderate | Inhibikase Therapeutics, Inc. | Arvind Kush director | $199k 145,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.